On November 4, 2026, IM Cannabis Corp. announced a significant financing move by entering into a Securities Purchase Agreement with an institutional investor. This agreement allowed the company to issue a convertible promissory note worth $1.2 million, convertible into common shares, along with a warrant to purchase additional shares. This financing is crucial for IM Cannabis as it seeks to strengthen its position in the competitive medicinal cannabis market.
IM Cannabis Corp., incorporated in Israel, operates in the medicinal chemicals and botanical products sector, specifically focusing on cannabis-based products. The company trades under the ticker IMCC on the Nasdaq exchange. With a recent filing dated November 4, 2026, this financing move is part of a broader strategy to secure funding for its operations and growth initiatives.
The filing details that the convertible note has a principal amount of $1.2 million with an original issuance discount of 15%. The company expects to receive net proceeds of approximately $1.02 million, which will be utilized for general corporate purposes. The note carries an interest rate of 4% per annum, which could increase to 14% in case of default. The investor has the option to convert the note into common shares at a fixed price of $0.610 per share, or at a variable price based on the lowest trading prices over the preceding 20 days.
This financing arrangement may impact various stakeholders, including shareholders, as the conversion of the note could lead to an increase in the number of outstanding shares. Additionally, the issuance of warrants allows the investor to purchase up to 3,936,330 common shares at the same exercise price, further diluting existing shareholders if exercised.
Looking ahead, IM Cannabis Corp. plans to file a resale registration statement with the SEC within 30 trading days following the closing of this financing. This statement will facilitate the resale of the common shares and warrant shares issued to the investor, enhancing liquidity and potentially attracting more investors.
Read Next
Rallybio Corp approves merger with Avenzo Therapeutics
FACT II Acquisition Corp. postpones extraordinary meeting
Wassil Jim Reports Stock Transactions for Vaxcyte, Inc.
Cowan Elvia Reports Stock Transactions in SEC Filing
Saiki Julie Reports New Stock Transactions at Azora Therapeutics
Davidson Acquires Over 524,000 Shares of Azora Therapeutics








